114 related articles for article (PubMed ID: 19046848)
1. [Pneumococcal infections and vaccination in patients with systemic autoimmune and/or inflammatory diseases].
Duchet-Niedziolka P; Hanslik T; Aouba A; Le Guern V; Guillevin L; Launay O;
Presse Med; 2009 Feb; 38(2):243-50. PubMed ID: 19046848
[TBL] [Abstract][Full Text] [Related]
2. New recommendations for pneumococcal vaccination in patients with autoimmune and inflammatory diseases.
Hernández-Flórez D; González-Benítez R; Valor L
Med Clin (Barc); 2017 Feb; 148(4):181-183. PubMed ID: 27931862
[No Abstract] [Full Text] [Related]
3. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.
Fedson DS; Nicolas-Spony L; Klemets P; van der Linden M; Marques A; Salleras L; Samson SI
Expert Rev Vaccines; 2011 Aug; 10(8):1143-67. PubMed ID: 21810065
[TBL] [Abstract][Full Text] [Related]
4. Nurse-led vaccination program dramatically improves pneumococcal vaccination coverage among patients with autoimmune inflammatory disorders.
Serre J; François C; der Haegen MCV; Papo T; Goulenok T; Sacre K
Eur J Intern Med; 2017 Sep; 43():e43-e45. PubMed ID: 28552464
[No Abstract] [Full Text] [Related]
5. Longterm Efficacy of an Antipneumococcal Polysaccharide Vaccine among Patients with Autoimmune Inflammatory Rheumatic Diseases.
Broyde A; Arad U; Madar-Balakirski N; Paran D; Kaufman I; Levartovsky D; Wigler I; Caspi D; Elkayam O
J Rheumatol; 2016 Feb; 43(2):267-72. PubMed ID: 26773117
[TBL] [Abstract][Full Text] [Related]
6. Pneumococcal conjugate vaccine for young children.
Selman S; Hayes D; Perin LA; Hayes WS
Manag Care; 2000 Sep; 9(9):49-52, 54, 56-7 passim. PubMed ID: 11116663
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in pneumococcal vaccination of children.
Russell FM; Mulholland EK
Ann Trop Paediatr; 2004 Dec; 24(4):283-94. PubMed ID: 15720885
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.
Jiang Y; Gauthier A; Keeping S; Carroll S
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):913-27. PubMed ID: 25189087
[TBL] [Abstract][Full Text] [Related]
9. [Flu vaccine and auto-immune and/or inflammatory diseases].
Duchet-Niedziolka P; Hanslik T; Mouthon L; Guillevin L; Launay O
Presse Med; 2011 Mar; 40(3):248-52. PubMed ID: 21232908
[TBL] [Abstract][Full Text] [Related]
10. Pneumococcal immunization in immunocompromised hosts: where do we stand?
Cordonnier C; Averbuch D; Maury S; Engelhard D
Expert Rev Vaccines; 2014 Jan; 13(1):59-74. PubMed ID: 24308578
[TBL] [Abstract][Full Text] [Related]
11. 7-valent pneumococcal conjugate vaccine: new preparation. Prevents rare invasive infections in infants.
Prescrire Int; 2002 Feb; 11(57):7-10. PubMed ID: 11985376
[TBL] [Abstract][Full Text] [Related]
12. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
[TBL] [Abstract][Full Text] [Related]
13. A public health and budget impact analysis of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.
Jiang Y; Gauthier A; Keeping S; Carroll S
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):901-11. PubMed ID: 25186657
[TBL] [Abstract][Full Text] [Related]
14. The risk of pneumococcal infections after immunization with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patients.
Nagel J; Geborek P; Saxne T; Jönsson G; Englund M; Petersson IF; Nilsson JÅ; Kapetanovic MC
Scand J Rheumatol; 2015; 44(4):271-9. PubMed ID: 25656734
[TBL] [Abstract][Full Text] [Related]
15. [Recommendations for prevention of community-acquired pneumonia with bacteremia as the leading form of invasive pneumococcal infections in the population of people over 50 years of age and risk groups above 19 years of age].
Albrecht P; Antczak A; Hryniewicz W; Skoczyńska A; Radzikowski A; Kedziora-Kornatowska K; Bernatowska E; Stompór T; Grodzicki T; Gyrczuk E; Imiela J; Jedrzejczak W; Windak A
Pol Merkur Lekarski; 2014 Feb; 36(212):79-87. PubMed ID: 24720101
[TBL] [Abstract][Full Text] [Related]
16. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.
Zangeneh TT; Baracco G; Al-Tawfiq JA
Expert Rev Vaccines; 2011 Mar; 10(3):345-53. PubMed ID: 21434802
[TBL] [Abstract][Full Text] [Related]
17. Sustained functional serotype-specific antibody after primary and secondary vaccinations with a pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease.
Ohshima N; Nagai H; Matsui H; Akashi S; Makino T; Akeda Y; Oishi K
Vaccine; 2014 Feb; 32(10):1181-6. PubMed ID: 24120483
[TBL] [Abstract][Full Text] [Related]
18. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children.
Thanee C; Pancharoen C; Likitnukul S; Luangwedchakarn V; Umrod P; Phasomsap C; Apornpong T; Chuanchareon T; Butterworth O; Puthanakit T
Vaccine; 2011 Aug; 29(35):5886-91. PubMed ID: 21729732
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus.
Elkayam O; Paran D; Caspi D; Litinsky I; Yaron M; Charboneau D; Rubins JB
Clin Infect Dis; 2002 Jan; 34(2):147-53. PubMed ID: 11740700
[TBL] [Abstract][Full Text] [Related]
20. Influenza and pneumococcal vaccine coverage among a random sample of hospitalised persons aged 65 years or more, Victoria.
Andrews RM; Skull SA; Byrnes GB; Campbell DA; Turner JL; McIntyre PB; Kelly HA
Commun Dis Intell Q Rep; 2005; 29(3):283-8. PubMed ID: 16220865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
